Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
Relmada Therapeutics (Nasdaq: RLMD) announced the presentation of clinical data for its lead product candidate, REL-1017, at the virtual American Psychiatric Association Annual Meeting from May 1-3, 2021. Two posters will be showcased: one on rapid antidepressant effects in Major Depressive Disorder (MDD), and another on therapeutic response related to life-years impacted by MDD. REL-1017, an NMDA receptor channel blocker, is in late-stage studies for adjunctive MDD treatment, with previous trials showing significant efficacy and safety.
- Clinical data for REL-1017 presented at an important psychiatric conference.
- Demonstrated rapid and sustained antidepressant effects in Phase 2 trials.
- Fast Track designation from FDA for REL-1017 indicates potential market advantage.
- None.
NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in two posters at the American Psychiatric Association (APA) Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021.
Details of the poster presentations are below:
Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET
Poster Number: 5181
Title: Rapid and Sustained Antidepressant Effects of REL-1017 (esmethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial
Date/Time: May 1, 2021, from 1:00 – 1:30 PM ET
Poster Number: 5198
Title: Effect of Percentage of Life-Years from the Start of Major Depressive Disorder on the Therapeutic Response of REL-1017
The on-demand posters are available for viewing online for the duration of the meeting by registered conference attendees.
About REL-1017
REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults. Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-poster-presentations-at-the-american-psychiatric-association-annual-meeting-2021-301281575.html
SOURCE Relmada Therapeutics, Inc.
FAQ
What are the key findings for REL-1017 presented by Relmada Therapeutics at the APA Annual Meeting 2021?
When was the APA Annual Meeting 2021 held where RLMD presented its findings?
What is Relmada Therapeutics' lead product candidate?
What is the significance of the Fast Track designation for REL-1017?
